Search clinical trials for: pembrolizumab (Keytruda)

Total 2270 results

Emory University
National Cancer Institute (NCI); Merck Sharp & Dohme LLC

Recruiting

Pembrolizumab as Salvage Therapy for the Treatment of Multiple Myeloma in Patients Progressing on CAR-T Cell Therapy

Plasma Cell Myeloma

United States
Medivir
Merck Sharp & Dohme LLC

Terminated

Dose-escalation Study of Birinapant and Pembrolizumab in Solid Tumors

Solid Tumors

United States
Emory University
National Cancer Institute (NCI); Merck Sharp & Dohme LLC; National Institutes...

Active, not recruiting

Pembrolizumab in Patients With Locally Advanced or Metastatic Skin Cancer

Recurrent Skin Carcinoma | Skin Squamous Cell Carcinoma

United States
Emory University
National Cancer Institute (NCI); National Institutes of Health (NIH); Exelixis

Active, not recruiting

Pembrolizumab & Cabozantinib in Patients With Head and Neck Squamous Cell Cancer

Recurrent Head and Neck Squamous Cell Carcinoma | Recurrent Hypopharyngeal Squamous Cell Carcinoma | Recurrent Laryngeal Squamous Cell Carcinoma | Recurrent Oral Cavity Squamous Cell Carcinoma | Recurrent Oropharyngeal Squamous Cell Carcinoma | Stage IV Hypopharyngeal Squamous Cell Carcinoma... and other conditions

United States
Vanderbilt-Ingram Cancer Center
National Cancer Institute (NCI)

Terminated

Pembrolizumab in Treating Patients With Advanced Uveal Melanoma

Stage IV Uveal Melanoma | Stage IIIA Uveal Melanoma | Stage IIIB Uveal Melanoma | Stage IIIC Uveal Melanoma

United States
University of Washington
National Cancer Institute (NCI)

Terminated

Pembrolizumab in Treating Minimal Residual Disease in Patients With Acute Lymphoblastic Leukemia

B Acute Lymphoblastic Leukemia | Recurrent Acute Lymphoblastic Leukemia | Minimal Residual Disease | T Acute Lymphoblastic Leukemia

United States
National Cancer Institute (NCI)

Completed

Pembrolizumab in Treating Patients With Relapsed or Refractory Stage IB-IVB Mycosis Fungoides or Sezary Syndrome

Recurrent Mycosis Fungoides and Sezary Syndrome | Refractory Mycosis Fungoides and Sezary Syndrome | Stage IB Mycosis Fungoides and Sezary Syndrome AJCC v7 | Stage IIA Mycosis Fungoides and Sezary Syndrome AJCC v7 | Stage IIB Mycosis Fungoides and Sezary Syndrome AJCC v7 | Stage IIIA Mycosis... and other conditions

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Withdrawn

Epacadostat and Pembrolizumab in Treating Participants With Advanced Pancreatic Cancer

Pancreatic Ductal Adenocarcinoma | Stage II Pancreatic Cancer AJCC v8 | Stage III Pancreatic Cancer AJCC v8 | Stage IV Pancreatic Cancer AJCC v8 | Homologous Recombination Deficiency | Stage IIA Pancreatic Cancer AJCC v8 | Stage IIB Pancreatic Cancer AJCC v8 | ATM Gene Mutation | Deleterious BRCA1 Gene... and other conditions
Rutgers, The State University of New Jersey
National Cancer Institute (NCI)

Recruiting

Pembrolizumab in Treating Participants With Metastatic, Recurrent or Locally Advanced Cancer and Genomic Instability

BRCA1 Gene Mutation | BRCA2 Gene Mutation | Recurrent Ovarian Carcinoma | Recurrent Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm | Stage IV Breast Cancer AJCC v6 and v7 | Stage III Breast Cancer AJCC v7 | Stage IIIA Breast Cancer AJCC v7 | Stage IIIB Breast Cancer AJCC v7 | Stage IIIC... and other conditions

United States
Barbara Ann Karmanos Cancer Institute
National Cancer Institute (NCI)

Completed

MK-3475 as Maintenance Therapy in Extensive Stage SCLC

Extensive Stage Small Cell Lung Carcinoma

United States
University of Erlangen-Nürnberg Medical School

Recruiting

Radiotherapy With Pembrolizumab in Metastatic HNSCC

Head and Neck Squamous Cell Carcinoma

Germany
University of Chicago
National Cancer Institute (NCI)

Active, not recruiting

Pembrolizumab in Treating Patients With Malignant Mesothelioma

Biphasic Mesothelioma | Epithelioid Mesothelioma | Peritoneal Malignant Mesothelioma | Pleural Biphasic Mesothelioma | Pleural Epithelioid Mesothelioma | Pleural Malignant Mesothelioma | Pleural Sarcomatoid Mesothelioma | Recurrent Peritoneal Malignant Mesothelioma | Recurrent Pleural Malignant Mesothelioma and other conditions

United States
Northwestern University
National Cancer Institute (NCI)

Terminated

Pembrolizumab and Pelareorep in Treating Patients With Advanced Pancreatic Cancer

Pancreatic Adenocarcinoma | Stage III Pancreatic Cancer AJCC v8 | Stage IV Pancreatic Cancer AJCC v8

United States
Abramson Cancer Center of the University of Pennsylvania

Completed

A Tissue Collection Study of Pembrolizumab (MK-3475) in Subjects With Resectable Advanced Melanoma

Malignant Melanoma

United States
Neurogene Inc.
Merck Sharp & Dohme LLC

Active, not recruiting

NL-201 Monotherapy and in Combination With Pembrolizumab in Patients With Relapsed or Refractory Cancer

Solid Tumor | Advanced Solid Tumor

United States, Australia, Canada
Jonsson Comprehensive Cancer Center
Merck Sharp & Dohme LLC

Completed

Pembrolizumab in Treating Patients With EGFR Mutant, Tyrosine Kinase Inhibitor Naive Advanced Non-Small Cell Lung Cancer

Stage IIIA Non-Small Cell Lung Cancer | Stage IIIB Non-Small Cell Lung Cancer | Stage IV Non-Small Cell Lung Cancer

United States
Sun Yat-sen University

Completed

Pharmacokinetically-guided on the Individualization of Pembrolizumab Administration in the Treatment of Lung Cancer

Non-small Cell Lung Cancer

China
Michael Boyiadzis
Merck Sharp & Dohme LLC

Withdrawn

Phase 0- Pilot Study of Pembrolizumab on Immune Cells in Patient With Refractory Acute Myeloid Leukemia

Refractory Acute Myeloid Leukemia

United States
Alfred Chung, MD
Merck Sharp & Dohme LLC

Terminated

Pembrolizumab for the Treatment of Relapsed or Refractory Multiple Myeloma After Anti-BCMA CAR-T Therapies

Multiple Myeloma | Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma | Multiple Myeloma in Relapse | Multiple Myeloma, Refractory

United States
Michael Boyiadzis
Merck Sharp & Dohme LLC

Completed

A Phase II Study of Pembrolizumab as Post-Remission Treatment of Patients ≥ 60 With AML

Acute Myeloid Leukemia

United States
The University of Hong Kong
Merck Sharp & Dohme LLC

Unknown

Pembrolizumab for T/NK-cell lymphomasNK-cell Lymphomas

T-Cell Lymphoma | NK-Cell Lymphoma

Hong Kong
Yana Najjar
Merck Sharp & Dohme LLC

Recruiting

A Trial of Pembrolizumab and Metformin Versus Pembrolizumab Alone in Advanced Melanoma

Advanced Melanoma

United States
CHA University
Merck Sharp & Dohme LLC

Not yet recruiting

Phase 2 Trial for Chemo-Resistant Gestational Trophoblastic Neoplasias With Pembrolizumab (CR-GTP) (CR-GTP)

Gestational Trophoblastic Neoplasia

Korea, Republic of
Silverback Therapeutics

Withdrawn

A Safety and Preliminary Efficacy Study of SBT6290 Alone and in Combination With PD-(L)1 Inhibitors in Select Advanced Solid Tumors

Squamous Cell Carcinoma of Head and Neck | Triple Negative Breast Cancer | Non-small Cell Lung Cancer | Urothelial Carcinoma | Hormone Receptor-positive/HER2-negative Breast Cancer
Tianjin Medical University Cancer Institute and...

Recruiting

Pembrolizumab in Post Radical Operation ESCC Patients With Lymph Node Positive ( KEYSTONE-004 )

ESCC | Adjuvant Treatment | Lymph Node Positive | Pembrolizumab

China
Binhui Biopharmaceutical Co., Ltd.

Recruiting

OH2 Injection in Solid Tumors

Melanoma | Solid Tumor

China
Samsung Medical Center

Completed

Study of Pembrolizumab in Subjects With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Who Progressed After First-Line Therapy With Platinum and Fluoropyrimidine: Integration of Molecular Subtypes Through Integrative Genomic Analysis

Gastric Adenocarcinoma | Gastroesophageal Junction Adenocarcinoma

Korea, Republic of
BerGenBio ASA
Merck Sharp & Dohme LLC

Terminated

Bemcentinib (BGB324) in Combination With Pembrolizumab in Patients With TNBC

Triple Negative Breast Cancer | Inflammatory Breast Cancer Stage IV

Spain, United States, United Kingdom, Norway
Jonsson Comprehensive Cancer Center
Merck Sharp & Dohme LLC

Recruiting

Pembrolizumab for the Treatment of Cervical Intraepithelial Neoplasia

Cervical Intraepithelial Neoplasia | Cervical Squamous Cell Carcinoma In Situ | Cervical Squamous Intraepithelial Neoplasia 2

United States
Roswell Park Cancer Institute

Active, not recruiting

Pembrolizumab Every 12 Weeks Versus Every 3 Weeks in Treating Patients With Non-small Cell Lung Cancer

Lung Non-Small Cell Carcinoma

United States
Joel Neal
Merck Sharp & Dohme LLC

Active, not recruiting

Pembrolizumab in Patients With Metastatic Non-squamous Non-small Cell Lung Cancer

Metastatic Non-Squamous Non-Small Cell Lung Carcinoma

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Pembrolizumab Before Surgery for the Treatment of Mismatch Repair Deficient Locally Advanced Solid Cancers

Locally Advanced Malignant Solid Neoplasm

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Pembrolizumab in Treating Patients With Bladder Cancer Undergoing Radical Cystectomy

Stage III Bladder Cancer AJCC v8 | Stage I Bladder Cancer AJCC v8 | Stage IIIA Bladder Cancer AJCC v8 | Stage IIIB Bladder Cancer AJCC v8 | Stage II Bladder Cancer AJCC v8

United States
Anne Chang
National Cancer Institute (NCI); Merck Sharp & Dohme LLC

Completed

Pembrolizumab With or Without Vismodegib in Treating Metastatic or Unresectable Basal Cell Skin Cancer

Skin Basal Cell Carcinoma

United States
Transgene
Merck Sharp & Dohme LLC; BioInvent International AB

Recruiting

A Clinical Trial Assessing BT-001 Alone and in Combination With Pembrolizumab in Metastatic or Advanced Solid Tumors

Melanoma | Soft Tissue Sarcoma | Non Small Cell Lung Cancer | Metastatic Cancer | Triple Negative Breast Cancer | Merkel Cell Carcinoma

France, Belgium
Compass Therapeutics
Iqvia Pty Ltd; Merck, Sharp & Dohme, LLC, Rahway, NJ USA

Recruiting

Study of CTX-471 as a Monotherapy or in Combination With Pembrolizumab in Patients Post PD-1/PD-L1 Inhibitors in Metastatic or Locally Advanced Malignancies

Melanoma | Head and Neck Cancer | Small Cell Lung Cancer | Metastatic Cancer | Mesothelioma | Non-small Cell Lung Cancer | Locally Advanced Solid Tumor

United States
Wakayama Medical University
Merck Sharp & Dohme LLC

Unknown

Pembrolizumab Plus Amurubicin in Patients With Refractory Small-cell Lung Cancer

Small Cell Lung Cancer Extensive Stage

Japan
Jonsson Comprehensive Cancer Center
Merck Sharp & Dohme LLC

Recruiting

Pembrolizumab in Treating Participants With Leukoplakia

Leukoplakia | Erythroleukoplakia | Verrucous Oral Leukoplakia

United States
Jonsson Comprehensive Cancer Center
Merck Sharp & Dohme LLC

Active, not recruiting

Pembrolizumab in Treating Participants With Recurrent Ovarian Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Pembrolizumab in Treating Patients With Metastatic or Unresectable Gastroesophageal Adenocarcinoma

Clinical Stage III Gastric Cancer AJCC v8 | Clinical Stage IV Gastric Cancer AJCC v8 | Metastatic Gastroesophageal Junction Adenocarcinoma | Unresectable Gastroesophageal Junction Adenocarcinoma | Gastroesophageal Junction Adenocarcinoma | Clinical Stage III Esophageal Adenocarcinoma AJCC v8 | Clinical Stage IV Esophageal Adenocarcinoma AJCC v8 and other conditions

United States
NGM Biopharmaceuticals, Inc
Merck Sharp & Dohme LLC

Recruiting

Study of NGM831 as Monotherapy and in Combination With Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors

Melanoma | Renal Cell Carcinoma | Cervical Cancer | Breast Cancer | Gastric Cancer | Pancreatic Cancer | Esophageal Cancer | Ovarian Cancer | Prostate Cancer | Mesothelioma | Squamous Cell Carcinoma of Head and Neck | Cholangiocarcinoma | Non-small Cell Lung Cancer | Colorectal Carcinoma | Bladder Urothelial Cancer | Endocervical...

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Pembrolizumab in Treating Participants With Unresectable Thymoma or Thymic Cancer

Stage III Thymoma AJCC v8 | Stage IIIA Thymoma AJCC v8 | Stage IIIB Thymoma AJCC v8 | Stage IV Thymoma AJCC v8 | Stage IVA Thymoma AJCC v8 | Stage IVB Thymoma AJCC v8 | Unresectable Thymic Carcinoma

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Pembrolizumab in Treating Patients With Hormone Receptor Positive, Localized Inflammatory Breast Cancer Who Are Receiving Hormone Therapy and Did Not Achieve a Pathological Complete Response to Chemotherapy

Anatomic Stage IIIB Breast Cancer AJCC v8 | Anatomic Stage IIIC Breast Cancer AJCC v8 | Prognostic Stage IIIB Breast Cancer AJCC v8 | Prognostic Stage IIIC Breast Cancer AJCC v8 | Breast Inflammatory Carcinoma

United States
Merck Sharp & Dohme LLC

Completed

Study of Pembrolizumab (MK-3475) in Participants With Advanced Urothelial Cancer (MK-3475-052/KEYNOTE-052)

Urothelial Cancer
Merck Sharp & Dohme LLC

Completed

Study of MK-3475 (Pembrolizumab) in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma After Treatment With Platinum-based and Cetuximab Therapy (MK-3475-055/KEYNOTE-055)

Head and Neck Squamous Cell Carcinoma
Merck Sharp & Dohme LLC

Terminated

Immunologic Determinants of Response to Pembrolizumab (MK-3475) in Advanced Melanoma (MK-3475-161/KEYNOTE-161)

Advanced Melanoma

United States
National Cancer Institute (NCI)
NRG Oncology

Active, not recruiting

Testing Whether the Combination of Two Immunotherapy Drugs Have Activity in Recurrent or Persistent Clear Cell Ovarian Cancer

Recurrent Ovarian Carcinoma | Malignant Ovarian Clear Cell Tumor

United States, Puerto Rico
Haider Mahdi
Mirati Therapeutics Inc.

Withdrawn

Pembrolizumab With Sitravatinib in Recurrent Endometrial Cancer and Other Solid Tumors With Deficient Mismatch Repair System

Solid Tumors | Recurrent Endometrial Cancer

United States
Seagen Inc.

Terminated

A Safety Study of SGN-2FF for Patients With Advanced Solid Tumors

Carcinoma, Renal Cell | Breast Neoplasms | Carcinoma, Non-Small-Cell Lung | Colorectal Neoplasms | Gastric Adenocarcinoma | Gastroesophageal Junction Adenocarcinoma | Carcinoma, Squamous Cell of Head and Neck | Urinary Bladder Neoplasm

United States
Regeneron Pharmaceuticals

Not yet recruiting

A Trial to Learn if Fianlimab and Cemiplimab Are Safe and Work Better Than Pembrolizumab in Adult Participants With Resectable Stage 3 or 4 Melanoma

Melanoma

Search clinical trials for: pembrolizumab (Keytruda)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Poland

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations